Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
"Looking back at 2023, I am proud to point out the significant steps we have made in our development, including the key achievements such as the CE-marking of LAMPlify® according to Low Voltage Directive (LVD) 2006/95/ EC. A highlight of our fourth quarter was the commencement of LAMPlify® commercialisation." says, Karin Wehlin, interim CEO Diagonal Bio AB.
Summary of Year-end Report 2023
2023-10-01 - 2023-12-31 (October - December)Net sales amounted to 23 KSEK (0 KSEK), capitalised development contributed with 405 KSEK (846 KSEK), while other operating income amounted to 7 KSEK (3 KSEK).
Operating profit amounted to -2 462 KSEK (-3 938 KSEK).
Operating profit per net weighted average share amounted to -0.06 SEK (-0.33 SEK).
Cash flow during the fourth quarter amounted to -1 745 KSEK (2 817 KSEK).
Cash and cash equivalents at the end of the period amounted to 2 972 KSEK (13 585 KSEK).
Net sales amounted to 23 KSEK (203 KSEK), capitalised development contributed with 3 128 KSEK (3 503 KSEK) and other operating income amounted to 25 KSEK (28 KSEK).
Operating profit amounted to -11 566 KSEK (-15 163 KSEK).
Operating profit per net weighted average share amounted to -0.32 SEK (-1.7 SEK).
Cash flow during the period amounted to -10 613 KSEK (-7 181 KSEK).
On November 14, 2023, Diagonal Bio announced the initiation of a pilot study with Techtum Lab AB to identify genetic markers for herpes and influenza viruses in horses.
On November 23, 2023, Diagonal Bio announced the appointment of board member Karin Wehlin as interim CEO, following a mutual agreement between the previous CEO and the board.
On November 27, 2023, Diagonal Bio communicated that the Company had signed an agreement with Hörsholms Hästepraksis for a paid test period using the LAMPlify® system, marking Diagonal Bio's first customer revenue.
On February 2, 2024, Diagonal Bio updated its financial situation, indicating efforts for a long-term financial solution to be announced in connection with the Year-end Report for 2023.
On February 16, 2024, Diagonal Bio signed a distribution agreement with Techtum Lab AB.
For additional information about Diagonal Bio AB
Please contact:
Karin Wehlin, Interim CEO
Phone: +46 703 052 488
E-mail: kw@diagonalbio.com
Kerstin Åkesson Jakobsson
Chair of the Board of Directors
Phone: +46 705 504 540
E-mail: kj@diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
Diagonal Bio is a Swedish Medtech company founded in 2020 with the vision to limit the spread of infectious diseases worldwide by creating an easy-to-use, cost-efficient, quick, and accurate platform technology based on Diagonal Bio's patented technology for detection of genetic markers.
At Diagonal Bio we are creating two separate product lines intended for different market segments: LAMPlify®️for the less regulated market segments; PANVIRAL®️ for the in-vitro diagnostic market segments.
www.diagonalbio.com